FAKHRAVAC
FAKHRAVAC is an Iranian-developed COVID-19 vaccine named in honor of the nuclear scientist Mohsen Fakhrizadeh, who was assassinated in November 2020. The vaccine was developed by the Organization of Defensive Innovation and Research, a part of Iran's Defense Ministry. FAKHRAVAC is part of Iran's extensive efforts to combat the COVID-19 pandemic, which has significantly impacted the country and the world at large.
Development and Efficacy[edit]
The development of FAKHRAVAC began shortly after the global spread of COVID-19. Iranian scientists aimed to create an effective vaccine to ensure the country's independence in managing the health crisis. The vaccine uses inactivated virus technology, a traditional method in vaccine development, where the virus is killed and then used to stimulate an immune response without causing the disease.
Clinical trials for FAKHRAVAC were conducted in several phases to evaluate its safety and efficacy. Although specific data from these trials have not been widely published in international peer-reviewed journals, Iranian authorities have reported that the vaccine shows considerable efficacy in preventing COVID-19 infections and reducing the severity of the disease in cases of breakthrough infections.
Approval and Distribution[edit]
FAKHRAVAC received emergency use authorization from Iran's health regulatory bodies, allowing for its distribution among the Iranian population. The vaccine's rollout is part of Iran's broader vaccination campaign, which also includes other domestically produced vaccines and imported vaccines.
Controversies and Challenges[edit]
The development and distribution of FAKHRAVAC have not been without controversy. The lack of published data from clinical trials has led to skepticism regarding the vaccine's reported efficacy and safety. Additionally, the vaccine's association with Iran's Defense Ministry and the naming after Mohsen Fakhrizadeh have sparked political debates both within Iran and internationally.
Despite these challenges, FAKHRAVAC represents a significant achievement for Iran's scientific community and its efforts to achieve self-sufficiency in vaccine production amid economic sanctions and geopolitical tensions.
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
